Navigation Links
New HAE Drug Candidate from Dyax Produced by Laureate Biopharma
Date:8/26/2013

PRINCETON, N.J., Aug. 26, 2013 /PRNewswire/ -- Laureate Biopharma is pleased to announce its successful collaboration with Dyax Corp. for process development and cGMP production of a new treatment candidate for hereditary angioedema (HAE).  The drug candidate, known as DX-2930, is a fully human IgG antibody designed to prevent HAE attacks by inhibition of plasma kallikrein. Dyax, a biopharmaceutical company focused on HAE and other plasma kallikrein disorders, recently announced the start of a Phase 1 clinical trial evaluating the safety and tolerability of DX-2930.

In working with the cell line producing DX-2930, Laureate's scientists were able to successfully scale-up and manufacture a high-titer antibody process. This process was amendable to cGMP production in both stainless-steel and single-use bioreactors. Application of Laureate's platform downstream process for IgG antibodies led to high protein recovery and purity. Aseptic filling, a routine operation at Laureate, produced the clinical drug product in 98% yield. Finally, careful project management of the program by both companies resulted in the successful release of bulk drug substance.

"Entry into human subjects is an important milestone for the DX-2930 development program," said Gustav Christensen, President and CEO of Dyax.  "It was a pleasure to work with Laureate's scientific and program management team.  This valuable partnership has enabled us to advance this fully human monoclonal antibody into the clinic and closer toward our goal of a new therapeutic for the prevention of HAE attacks."

"This project showcased Laureate's scientific expertise in rapid development of efficient, high-yielding processes for clinical production of therapeutic antibodies," noted Michiel E. Ultee, Ph.D., Laureate's Chief Scientific Officer. "Our scientists have produced a wide variety of antibodies for more than 30 years, including IgG, IgM, fragmented (Fab & F(ab')2), conjugated, aglycosylated and domain-deleted antibodies."

About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit www.LBioS.com.

About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs.  The Company's key value drivers are the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Program (LFRP).

For additional information about Dyax, please visit www.dyax.com.

For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.

For more information, contact: Michiel E. Ultee, Ph.D., Chief Scientific Officer, Laureate Biopharma, at (609) 919-3390 or info@LBioS.com, or visit www.LBioS.com.


'/>"/>
SOURCE Laureate Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
4. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
5. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
6. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
7. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
8. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
9. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
10. Test Results Show Unprecedented Achievement for Marburg Drug Candidate
11. As Tuberculosis Grows More Difficult to Control, Vaccine Candidate to Prevent Disease Enters Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):